Janssen to Address NICE's Concerns Following Another English Funding No For Spravato

 
• By Kevin Grogan

UK health technology assessment body NICE says the cost-effectiveness estimates for the nasal spray for treating hard-to-treat depression are much higher than what it considers to be cost-effective.

Target
J&J gets another go with NICE for Spravato • Source: Shutterstock

More from Health Technology Assessment

More from Market Access